Transaction in Own Shares

PureTech Health PLC
13 November 2023
 

13 November 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:             

10 November 2023



Number of ordinary shares purchased:

42,611



Highest price paid per share:

171.40p



Lowest price paid per share:

162.80p



Volume weighted average price paid per share:

164.81p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,239,318 ordinary shares in treasury and has 273,228,841 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 273,228,841 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

10/11/2023

08:27:20

210

171.4

AQXE

00377884364TRLO0.1.1

10/11/2023

08:27:20

469

171.4

BATE

00377884365TRLO0.1.1

10/11/2023

08:27:20

97

170.2

TRQX

00377884366TRLO0.1.1

10/11/2023

08:27:20

469

169.6

CHIX

00377884369TRLO0.1.1

10/11/2023

08:27:20

469

171

XLON

00377884367TRLO0.1.1

10/11/2023

08:38:02

469

166.6

XLON

00377886852TRLO0.1.1

10/11/2023

09:06:52

31

167.4

XLON

00377892471TRLO0.1.1

10/11/2023

09:06:52

469

167.4

XLON

00377892473TRLO0.1.1

10/11/2023

09:06:52

438

167.4

XLON

00377892472TRLO0.1.1

10/11/2023

09:39:03

938

165.2

XLON

00377897673TRLO0.1.1

10/11/2023

09:39:04

469

165.2

BATE

00377897679TRLO0.1.1

10/11/2023

09:40:16

291

165.2

CHIX

00377897904TRLO0.1.1

10/11/2023

10:16:41

49

166.2

CHIX

00377905104TRLO0.1.1

10/11/2023

10:35:53

210

166.2

AQXE

00377908534TRLO0.1.1

10/11/2023

10:35:53

420

166.2

CHIX

00377908535TRLO0.1.1

10/11/2023

11:32:52

210

166

AQXE

00377916583TRLO0.1.1

10/11/2023

11:32:52

64

166

CHIX

00377916585TRLO0.1.1

10/11/2023

11:32:52

583

166

CHIX

00377916584TRLO0.1.1

10/11/2023

11:32:52

132

166

CHIX

00377916586TRLO0.1.1

10/11/2023

11:32:57

1488

166.6

XLON

00377916596TRLO0.1.1

10/11/2023

11:32:57

1321

166.6

XLON

00377916597TRLO0.1.1

10/11/2023

11:33:14

1035

165.6

XLON

00377916628TRLO0.1.1

10/11/2023

11:48:14

372

165.6

XLON

00377918999TRLO0.1.1

10/11/2023

11:48:14

27

165.6

XLON

00377919000TRLO0.1.1

10/11/2023

11:48:14

985

165.6

XLON

00377919001TRLO0.1.1

10/11/2023

11:48:14

871

165.6

XLON

00377919002TRLO0.1.1

10/11/2023

11:48:14

936

165.6

XLON

00377919003TRLO0.1.1

10/11/2023

11:48:14

469

165.2

BATE

00377919005TRLO0.1.1

10/11/2023

11:48:14

469

165.2

BATE

00377919004TRLO0.1.1

10/11/2023

11:49:48

97

166

TRQX

00377919247TRLO0.1.1

10/11/2023

11:55:46

22

164.8

TRQX

00377920126TRLO0.1.1

10/11/2023

11:55:46

75

164.8

TRQX

00377920128TRLO0.1.1

10/11/2023

11:55:46

1407

165

XLON

00377920127TRLO0.1.1

10/11/2023

12:15:29

123

165.2

XLON

00377924673TRLO0.1.1

10/11/2023

12:17:04

23

165.2

XLON

00377925190TRLO0.1.1

10/11/2023

12:20:52

559

165.2

XLON

00377926338TRLO0.1.1

10/11/2023

12:27:40

24

164.6

TRQX

00377927982TRLO0.1.1

10/11/2023

12:27:41

73

164.6

TRQX

00377927986TRLO0.1.1

10/11/2023

12:27:41

1407

164.6

XLON

00377927987TRLO0.1.1

10/11/2023

12:28:02

172

164

BATE

00377928080TRLO0.1.1

10/11/2023

12:28:02

158

164

CHIX

00377928081TRLO0.1.1

10/11/2023

12:28:02

116

164

CHIX

00377928082TRLO0.1.1

10/11/2023

12:28:02

515

164

CHIX

00377928083TRLO0.1.1

10/11/2023

12:28:02

17

164

CHIX

00377928084TRLO0.1.1

10/11/2023

12:28:02

297

164

BATE

00377928085TRLO0.1.1

10/11/2023

12:28:48

210

163.6

AQXE

00377928210TRLO0.1.1

10/11/2023

12:28:48

196

163.6

AQXE

00377928209TRLO0.1.1

10/11/2023

12:31:13

291

164

XLON

00377928568TRLO0.1.1

10/11/2023

12:31:13

231

164

XLON

00377928569TRLO0.1.1

10/11/2023

12:41:28

123

164

XLON

00377930529TRLO0.1.1

10/11/2023

12:42:22

580

164

XLON

00377930644TRLO0.1.1

10/11/2023

12:43:34

212

164

XLON

00377930839TRLO0.1.1

10/11/2023

12:58:33

938

163.6

XLON

00377933761TRLO0.1.1

10/11/2023

13:04:03

1141

163

XLON

00377934911TRLO0.1.1

10/11/2023

13:04:04

17

162.8

TRQX

00377934917TRLO0.1.1

10/11/2023

13:12:55

79

162.8

TRQX

00377936203TRLO0.1.1

10/11/2023

13:23:21

183

163

XLON

00377937832TRLO0.1.1

10/11/2023

13:23:21

286

163

XLON

00377937831TRLO0.1.1

10/11/2023

13:34:04

201

163

XLON

00377939578TRLO0.1.1

10/11/2023

14:06:41

67

164.4

CHIX

00377946381TRLO0.1.1

10/11/2023

14:34:47

208

163.8

CHIX

00377956468TRLO0.1.1

10/11/2023

14:35:40

261

163.8

CHIX

00377957225TRLO0.1.1

10/11/2023

14:35:40

64

163.8

CHIX

00377957226TRLO0.1.1

10/11/2023

14:35:40

467

163.8

CHIX

00377957227TRLO0.1.1

10/11/2023

14:35:40

210

163.8

AQXE

00377957229TRLO0.1.1

10/11/2023

14:35:40

1407

163.8

XLON

00377957228TRLO0.1.1

10/11/2023

14:36:04

220

163.6

BATE

00377957819TRLO0.1.1

10/11/2023

14:43:07

200

163.6

BATE

00377964092TRLO0.1.1

10/11/2023

15:02:29

469

165

CHIX

00377972744TRLO0.1.1

10/11/2023

15:02:29

210

164.8

AQXE

00377972746TRLO0.1.1

10/11/2023

15:02:29

469

165

CHIX

00377972745TRLO0.1.1

10/11/2023

15:02:29

1407

164.8

XLON

00377972747TRLO0.1.1

10/11/2023

15:02:29

384

164.4

BATE

00377972749TRLO0.1.1

10/11/2023

15:02:29

73

164.4

BATE

00377972748TRLO0.1.1

10/11/2023

15:02:29

12

164.4

BATE

00377972750TRLO0.1.1

10/11/2023

15:02:29

53

164.4

BATE

00377972751TRLO0.1.1

10/11/2023

15:02:29

57

164.4

BATE

00377972752TRLO0.1.1

10/11/2023

15:03:24

266

164.4

BATE

00377973195TRLO0.1.1

10/11/2023

15:03:24

97

164.2

TRQX

00377973196TRLO0.1.1

10/11/2023

15:11:42

240

164

XLON

00377977775TRLO0.1.1

10/11/2023

15:11:42

201

164

XLON

00377977776TRLO0.1.1

10/11/2023

15:17:45

19

163.8

XLON

00377980192TRLO0.1.1

10/11/2023

15:17:53

98

164

TRQX

00377980233TRLO0.1.1

10/11/2023

15:19:43

200

163.8

XLON

00377981054TRLO0.1.1

10/11/2023

15:27:10

267

163.4

CHIX

00377983978TRLO0.1.1

10/11/2023

15:27:10

542

163.4

CHIX

00377983979TRLO0.1.1

10/11/2023

15:27:10

469

163.4

XLON

00377983980TRLO0.1.1

10/11/2023

15:27:10

210

163.4

AQXE

00377983981TRLO0.1.1

10/11/2023

15:28:28

68

163

XLON

00377984546TRLO0.1.1

10/11/2023

15:31:08

97

164

TRQX

00377985528TRLO0.1.1

10/11/2023

15:32:38

29

163.6

XLON

00377985956TRLO0.1.1

10/11/2023

15:32:56

29

163.6

XLON

00377986163TRLO0.1.1

10/11/2023

15:35:00

446

164.4

BATE

00377986761TRLO0.1.1

10/11/2023

15:51:44

215

163.6

XLON

00377996251TRLO0.1.1

10/11/2023

15:51:44

350

163.6

XLON

00377996250TRLO0.1.1

10/11/2023

15:51:44

56

162.8

BATE

00377996252TRLO0.1.1

10/11/2023

15:51:44

938

162.8

XLON

00377996254TRLO0.1.1

10/11/2023

15:51:44

302

163.6

XLON

00377996253TRLO0.1.1

10/11/2023

15:51:44

97

162.8

TRQX

00377996255TRLO0.1.1

10/11/2023

15:51:44

97

162.8

TRQX

00377996256TRLO0.1.1

10/11/2023

15:53:05

72

163

AQXE

00377997315TRLO0.1.1

10/11/2023

15:58:00

69

163

AQXE

00378000050TRLO0.1.1

10/11/2023

15:58:43

455

163

BATE

00378000314TRLO0.1.1

10/11/2023

15:59:08

190

163

AQXE

00378000482TRLO0.1.1

10/11/2023

15:59:08

69

163

AQXE

00378000481TRLO0.1.1

10/11/2023

15:59:08

14

163

BATE

00378000483TRLO0.1.1

10/11/2023

16:02:15

58

162.8

XLON

00378001890TRLO0.1.1

10/11/2023

16:03:40

1349

162.8

XLON

00378002596TRLO0.1.1

10/11/2023

16:27:40

938

164

XLON

00378021235TRLO0.1.1

10/11/2023

16:29:25

242

163.8

CHIX

00378022177TRLO0.1.1

10/11/2023

16:29:48

937

164

XLON

00378022739TRLO0.1.1

10/11/2023

16:29:49

83

164

XLON

00378022749TRLO0.1.1

10/11/2023

16:29:49

2277

164

XLON

00378022750TRLO0.1.1

10/11/2023

16:29:57

54

164

XLON

00378022910TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings